FMP
Pacific Biosciences of California, Inc.
PACB
NASDAQ
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
1.36 USD
-0.02 (-1.47%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
78.89M
130.51M
128.3M
200.52M
154.01M
191.3M
237.61M
295.12M
366.57M
455.3M
-
65.43
-1.69
56.29
-23.19
24.21
24.21
24.21
24.21
38.97M
-250.76M
-282.24M
-277.28M
-356.38M
-134.14M
-166.61M
-206.94M
-257.04M
-319.26M
49.4
-192.13
-219.98
-138.28
-231.4
-70.12
-70.12
-70.12
-70.12
29.67M
-262.34M
-299.56M
-303.82M
-409.73M
-138.65M
-172.21M
-213.9M
-265.68M
-330M
37.61
-201.01
-233.48
-151.51
-266.04
-72.48
-72.48
-72.48
-72.48
9.3M
11.59M
17.32M
26.53M
53.35M
31.39M
38.99M
48.42M
60.15M
74.71M
11.79
8.88
13.5
13.23
34.64
16.41
16.41
16.41
16.41
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)